BUSINESS

• 38% of Complete Response Patients Remained in Remission for 5-Plus Years: Adcetris PII
  July 20, 2016

• US FDA OKs Once-Daily Belviq: Eisai
  July 20, 2016

• FDA, EMA Accept Opdivo Filing for Head and Neck Cancer
  July 20, 2016

• Bayer, Taisho Join Hands on Switch OTC Version of Claritin
  July 19, 2016

• Daiichi Sankyo to Commercialize Amgen’s 9 Investigational Biosimilars Including Adalimumab in Japan
  July 15, 2016

• AnGes MG, Osaka Univ. Team Up for Joint Research on Novel Drug Delivery System
  July 15, 2016

• Takeda Launches Awareness Campaign for Inflammatory Bowel Disease in Europe, US
  July 14, 2016

• Not Much Difference in Efficacy, Safety between 2 PCSK9 Inhibitors: Dr Teramoto of Teikyo University
  July 14, 2016

• SymBio Earns Sales Milestone for Bendamustine from Taiwanese Firm
  July 13, 2016

• “Limited Potential for Growth through Domestic Business Alone” Is Reason for Acquiring US Generic Maker: Nichi-Iko Pres.
  July 13, 2016

• AnGes MG to Develop Chimera Decoy for World’s 1st Simultaneous Inhibition of Multiple Targets as Anti-Inflammatory Therapies
  July 13, 2016

• Ono Gets Rights to Celyad’s Allogeneic CAR T-cell Therapy
  July 12, 2016

• Kyorin to Copromote Allergy Drug Desloratadine with Kaken
  July 12, 2016

• Medreich’s Japan-Bound Generics Plant in India Completed: Meiji
  July 12, 2016

• Nichi-Iko to Buy Sagent for US$736 Million
  July 12, 2016

• 1st Patients Randomized in PII Cell Therapy Trial for Traumatic Brain Injury: SanBio
  July 12, 2016

• Ethical Drug Sales Up 5.8% in May: Crecon Report
  July 12, 2016

• Kyorin Eager to Resurrect Drug Discovery Prowess, Says President
  July 11, 2016

• Nippon Chemiphar to Boost Generic Production to 2 Billion Tablets by FY2018: President
  July 11, 2016

• NTD Collaboration with Astellas Began by Coincidence: Merck Global Health R&D Chief
  July 11, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 484
• 485
• 486
• 487
• 488
• 489
• 490
• 491
• 492
• …
• Next ›
• 最終 »